Melanotan II Research Guide Ireland

Overview

Melanotan II (MT-II) is a synthetic cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH). It is a non-selective melanocortin receptor agonist, meaning it activates multiple melanocortin receptor subtypes at once — MC1R, MC3R, and MC4R — rather than targeting one selectively.

Melanotan II is not approved by any medicines regulator anywhere in the world for any indication. It is not approved by the FDA, not approved by the EMA, and not approved by Ireland's Health Products Regulatory Authority (HPRA). It has no licensed medicinal use. In practice, it circulates almost exclusively through unregulated, grey-market and black-market channels, most commonly marketed informally as an injectable "tanning" product and, less commonly, for its libido-related effects. Nothing in this guide should be read as an endorsement of its use — the purpose here is to document what has actually been studied and what is known about its risks.

Melanotan II's clinical relevance today is largely historical: it was the parent research compound from which a more receptor-selective, regulator-reviewed molecule — PT-141 (bremelanotide) — was later derived and refined for the treatment of hypoactive sexual desire disorder (HSDD) in women. That refinement effort happened specifically because Melanotan II's non-selective receptor activity was considered too broad and too unpredictable for pharmaceutical development.

Clinical & Research Status

Mechanism of Action

Melanotan II is a broad, non-selective melanocortin receptor agonist. It activates MC1R on melanocytes, which drives melanogenesis — the production of melanin — producing skin darkening without the need for UV exposure. It simultaneously activates MC3R and MC4R in the hypothalamus, receptors that are part of the pathways linked to appetite regulation and sexual arousal.

This lack of receptor selectivity is the central mechanistic feature to understand: it is precisely why Melanotan II produces both a tanning effect (via MC1R) and a libido/arousal effect (via MC4R) in the same molecule, and it is also why its side-effect profile is broader and less predictable than more selective successor compounds. Bremelanotide (PT-141) was later developed specifically to isolate the MC4R-driven arousal effect while minimising the off-target MC1R and MC3R activity that contributes to Melanotan II's pigmentation changes and other effects.

Research Areas & Reported Effects

Tanning / Photoprotection Research

Melanotan II's origins trace back to research at the University of Arizona under Mac E. Hadley and colleagues, who investigated melanotropic peptides as potential non-UV agents to induce melanogenesis — with an original research rationale centred on skin cancer prevention via increased natural pigmentation, rather than cosmetic tanning. The compound later leaked out of formal research channels into unregulated cosmetic and bodybuilding markets, where it is now used almost exclusively for its tanning effect, entirely outside any research or medical oversight.

Libido and Sexual Dysfunction Research

Early human studies examined Melanotan II's effect on erectile function and sexual arousal in men, providing proof-of-concept evidence that melanocortin receptor activation could drive sexual arousal independent of the vascular mechanisms targeted by drugs like sildenafil. This work is historically significant because it directly informed the later development of bremelanotide (PT-141) as a more selective, better-tolerated molecule for HSDD.

Appetite and Energy Balance (Preclinical)

MC3R and MC4R are established regulators of feeding behaviour and energy balance in preclinical models. Melanotan II's activity at these receptors has made it a reference tool compound in melanocortin pathway research, though this has not translated into any approved appetite-related therapeutic use.

Documented Adverse Effects in Case Reports

Because Melanotan II is used almost exclusively outside regulated settings, much of what is known about its real-world risk comes from case reports rather than controlled trials. Dermatology and toxicology literature has documented concerns including new or changing pigmented lesions (raising melanoma surveillance concerns), and case reports describing acute kidney injury associated with unregulated injectable use. This is case-report-level evidence, not randomised trial data, and should be weighted accordingly — but it is consistent and recurring enough to be a genuine safety signal.

Research Data Summary

Stack Combinations Studied

• No legitimate clinical research has studied Melanotan II in combination with other peptides or compounds.
• Grey-market sources sometimes reference informal combination with other tanning or libido-oriented compounds — this is anecdotal, not research-derived, and carries compounded unknown risk from unregulated products.

⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.

Research Protocol Reference

Historical experimental research protocols only — not dosing recommendations.

Observed Side Effects in Research

• Nausea and vomiting — very common, particularly with early doses
• Facial flushing
• Spontaneous or prolonged erections, including documented priapism
• New or changing moles and pigmented lesions — a documented melanoma surveillance concern
• Appetite suppression
• General skin darkening, including darkening of existing freckles and moles
• Stretching and yawning — an unusual but reported CNS-mediated effect
• Case reports of acute kidney injury associated with unregulated injectable use
• Unknown purity and contamination risk, since supply is entirely unregulated and manufacturing is not overseen by any medicines authority

Because Melanotan II has no approved medical use anywhere, there is no regulator-reviewed safety monitoring of any product sold as "Melanotan II." Anyone considering its use should be aware that documented case reports include serious events, and that product quality, dose accuracy, and contamination status cannot be verified for grey-market sources.

Compound Data

CAS Number

121062-08-6

Molecular Formula

C50H69N15O9

Molecular Weight

~1024.2 g/mol

Half-Life

Short per injection (minutes to a few hours); repeated dosing needed to sustain pigmentation effect — exact human PK not formally established outside small pilot studies

Synonyms

Melanotan-II, MT-II, MT2

Research Classification

Non-selective melanocortin receptor agonist (MC1R/MC3R/MC4R), cyclic heptapeptide, alpha-MSH analogue

Scientific References

• Dorr RT, Lines R, Levine N, et al. [1996] — Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. — Life Sciences — [Human pilot study]
• Wessells H, Gralnek D, Dorr R, et al. [1998–2000] — Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan-II. — International Journal of Impotence Research / Journal of Urology — [Human proof-of-concept study]
• Hadley ME, Dorr RT [2006] — Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. — Peptides — [Review]
• Dermatology and toxicology case-report literature (2010s) — Reports of melanocytic lesion changes and acute kidney injury in unregulated Melanotan II users. — Various dermatology/toxicology journals — [Case report level evidence, not RCT data]

This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.